Výsledky vyhledávání

P414 Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn′s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study

Autor: B Bokemeyer, S Plachta-Danielzik, P Efken, W Mohl, M Hoffstadt, T Krause, A Schweitzer, E Schnoy, R Atreya, N Teich, L Trentmann, R Ehehalt, S Franzenburg, P Hartmann, R di Giuseppe, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 17:i543-i544

Background To gain insight into vedolizumab (VEDO) use as a first-line biologic in Crohn′s disease (CD), this comparative, two-arm prospective real-world-evidence (RWE) study with propensity score (PS) adjustment aimed to assess, within the mainten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60bc42ec04155e0bfecf0e4601aaf691
https://doi.org/10.1093/ecco-jcc/jjac190.0544

Zobrazit plný text záznamu

P742 Real-world evidence comparison on the effectiveness of ustekinumab vs anti-TNF or vedolizumab in ulcerative colitis: induction phase results from the prospective, observational RUN-UC study

Autor: B Bokemeyer, S Plachta-Danielzek, S Howaldt, W Mohl, P Efken, R Ehehalt, M Kahl, T Krause, L Trentmann, A Lügering, E Schnoy, C Jochum, S Fajardo Salmon, P Hartmann, E Gilman, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 17:i872-i873

Background Observational real-world evidence (RWE) studies on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are required in addition to RCTs, which are usually confined to selected patients and thus may not represent di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b89406dec8b42dc8297ec36d10282045
https://doi.org/10.1093/ecco-jcc/jjac190.0872

Zobrazit plný text záznamu

P801 Maintenance phase effectiveness and persistence after two years in biologic-naïve ulcerative colitis patients treated with vedolizumab or anti-TNF (VEDO-IBD-study)

Autor: S Plachta-Danielzik, B Bokemeyer, P Efken, W Mohl, T Krause, M Hoffstadt, R Ehehalt, L Trentmann, A Schweitzer, P Jessen, S Franzenburg, P Hartmann, R di Giuseppe, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 17:i933-i934

Background In this two-arm prospective real-world-evidence (RWE) study with propensity score adjustment, we aimed to analyse the persistence of biologic therapy in biologic-naïve ulcerative colitis (UC) patients and to compare the 2-year effectivene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7bdb558bb20566aadf0d78e0dc281da
https://doi.org/10.1093/ecco-jcc/jjac190.0931

Zobrazit plný text záznamu

P784 Real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD study

Autor: S Plachta-Danielzik, B Bokemeyer, P Efken, W Mohl, M Hoffstadt, T Krause, A Schweitzer, E Schnoy, R Ehehalt, L Trentmann, N Teich, R Atreya, S Franzenburg, P Hartmann, T Wenske, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 17:i918-i919

Background Since April 2020, vedolizumab (VEDO) has been available for use in IBD in intravenous (iv) and subcutaneous (sc) formulations. Due to limited data on real-world use and effectiveness, the objectives of this real-world evidence (RWE), obser

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15dd84544f316d5caebd44a8fd1c6a95
https://doi.org/10.1093/ecco-jcc/jjac190.0914

Zobrazit plný text záznamu

OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study

Autor: B Bokemeyer, S Plachta-Danielzik, H Deppe, W Mohl, N Teich, M Hoffstadt, A Schweitzer, M von der Ohe, A Gauss, R Atreya, T Krause, I Blumenstein, S Fajardo Salmon, P Hartmann, E Gilman, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 17:i50-i50

Background Within the framework of the prospective real-world RUN-CD registry on the effectiveness and safety of ustekinumab (UST) in Crohn’s disease (CD), a total of 901 CD-patients undergoing a newly initiated biologics therapy were enrolled in 4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c89d4927ecfb6f0db70cd0a66fa7ca26
https://doi.org/10.1093/ecco-jcc/jjac190.0036

Zobrazit plný text záznamu

Die Patientenperspektive in der Behandlung von Morbus Crohn: Ein Discrete Choice Experiment zur Erhebung von Therapiepräferenzen in Deutschland

Autor: S. Schubert, T Cavlar, J Knop, A Kahraman, N. Picker, W Mohl

Publikováno v: Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::34a816406c0c3b6f5c1fc21c9682d4ad
https://doi.org/10.1055/s-0041-1733530

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

DOP77 Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn′s Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study

Autor: R Di Giuseppe, S Plachta-Danielzik, B Bokemeyer, P Efken, W Mohl, M Hoffstadt, T Krause, A Schweitzer, E Schnoy, R Atreya, N Teich, L Trentmann, R Ehehalt, S Franzenburg, P Hartmann, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 16:i120-i121

Background To gain insight into vedolizumab (VDZ) use as a first-line biologic in Crohn′s Disease (CD), this real-world study aimed to assess, within the maintenance phase, the 1-year comparative effectiveness and persistence of VDZ vs anti-TNF the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe07049445fe06863f171fbe5c54f78a
https://doi.org/10.1093/ecco-jcc/jjab232.116

Zobrazit plný text záznamu

P601 Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study

Autor: B Bokemeyer, S Plachta-Danielzik, R di Giuseppe, H Deppe, W Mohl, N Teich, M Hoffstadt, A Schweitzer, M von der Ohe, A Gauss, R Atrya, T Krause, I Blumenstein, J Höchstödter, P Hartmann, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 16:i534-i535

Background Observational real world studies are required in addition to RCTs which typically represent selected patients not reflecting everyday clinical practice. Between 2017–2020 patients with Crohn’s disease (CD) receiving a newly initiated b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe6eac190442cf0e35dbc3cc466f3f49
https://doi.org/10.1093/ecco-jcc/jjab232.727

Zobrazit plný text záznamu

OP17 Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study)

Autor: S Plachta-Danielzik, R di Giuseppe, B Bokemeyer, P Efken, W Mohl, T Krause, M Hoffstadt, R Ehehalt, L Trentmann, A Schweitzer, P Jessen, S Franzenburg, P Hartmann, S Schreiber

Publikováno v: Journal of Crohn's and Colitis. 16:i018-i019

Background In this real-world-evidence (RWE) study we aimed to analyse the persistence of biologic therapy in biologic-naïve ulcerative colitis (UC) patients and to compare 1-year effectiveness of vedolizumab (VDZ) and anti-TNF. Methods Between 2017

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6bc26056c1b6498e960f6c1b1a6d60f7
https://doi.org/10.1093/ecco-jcc/jjab232.016

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání